Quantcast

Latest Jazz Pharmaceuticals plc Stories

2014-07-22 16:27:22

DUBLIN, July 22, 2014 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2014 second quarter financial results on Tuesday, August 5, 2014, after the close of the financial markets. Company management will host a live audio webcast immediately following the announcement at 4:30 p.m. EDT/9:30 p.m. IST to provide a business and financial update and discuss second quarter 2014 financial results. Interested parties may access the live audio...

2014-07-02 08:27:01

Jazz Pharmaceuticals to own worldwide rights to defibrotide at closing DUBLIN, July 2, 2014 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company has signed a definitive agreement with Sigma-Tau Pharmaceuticals, Inc. (Sigma-Tau) under which a subsidiary of Jazz Pharmaceuticals plc (Jazz) will acquire from Sigma-Tau rights to defibrotide in the United States (U.S.) and all other countries in the Americas. Sigma-Tau holds rights to market...

2014-06-02 16:25:34

Study Demonstrated Robust Alerting Effect Consistent with Phase 2a Results DUBLIN, June 2, 2014 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today presented data from the Phase 2b study evaluating JZP-110 (formerly known as ADX-N05) as a potential new treatment for the symptoms of excessive daytime sleepiness (EDS) in adults with narcolepsy. In the study, all primary and secondary endpoints were met and patients treated with JZP-110 experienced statistically significant...

2014-05-27 16:25:39

Phase 2b Data for JZP-110 in Adults with EDS in Narcolepsy Accepted as Late-Breaker Oral Presentation DUBLIN, May 27, 2014 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) announced today that new data for the investigational compound JZP-110 (previously ADX-N05) will be presented at the 28th Associated Professional Sleep Societies (APSS) Annual SLEEP Meeting, May 31 to June 4, 2014 in Minneapolis, Minn. The JZP-110 abstract was accepted as a late-breaker oral presentation. The...

2014-05-19 16:23:46

DUBLIN, May 19, 2014 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced the appointment of Russell J. Cox to the newly created position of chief operating officer (COO). Mr. Cox, who joined Jazz Pharmaceuticals in July 2010, most recently served as executive vice president and chief commercial officer at the company. He will continue to report to Bruce Cozadd, chairman and chief executive officer, and will now have global responsibility for the commercial,...

2014-05-13 20:23:14

DUBLIN, May 13, 2014 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will be webcasting its corporate presentations at two upcoming investor conferences. -- UBS Global Healthcare Conference in New York, NY on Tuesday, May 20, 2014 at 8:00 a.m. EDT / 1:00 p.m. IST. Matt Young, senior vice president and chief financial officer, will provide an overview of the company and a business and financial update. -- Goldman...

2014-05-08 16:27:24

Company Reports First Quarter 2014 Total Revenues of $247 Million Driven by Strong Sales of Xyrem, Erwinaze and Defibrotide DUBLIN, May 8, 2014 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the first quarter ended March 31, 2014 and reaffirmed and updated financial guidance for 2014. "We are pleased with the progress made during the first quarter, highlighted by the completion of two transactions that have positioned us well for both near- and...

2014-04-24 16:29:35

DUBLIN, April 24, 2014 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2014 first quarter financial results on Thursday, May 8, 2014, after the close of the financial markets. Company management will host a live audio webcast immediately following the announcement at 4:30 p.m. EDT/9:30 p.m. IST to provide a business and financial update and discuss first quarter 2014 financial results. Interested parties may access the live audio...

2014-03-31 08:29:52

Defitelio®? (defibrotide) Launch Announced During the 40th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 2014 DUBLIN and VILLA GUARDIA, Italy, March 31, 2014 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) and Gentium S.p.A., a Jazz Pharmaceuticals company, today announced the commencement of the European commercial launch of Defitelio®(?) (defibrotide), the first licensed product for the treatment of severe hepatic veno-occlusive...

2014-02-26 20:22:14

DUBLIN, Feb. 26, 2014 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will be webcasting its corporate presentations at two upcoming investor conferences. -- Cowen and Company 34(th) Annual Healthcare Conference in Boston, MA on Wednesday, March 5, 2014 at 8:00 a.m. EST / 1:00 p.m. GMT. Matt Young, senior vice president, corporate development, will provide an overview of the company and a business and financial update....


Word of the Day
siliqua
  • A Roman unit of weight, 1⁄1728 of a pound.
  • A weight of four grains used in weighing gold and precious stones; a carat.
  • In anatomy, a formation suggesting a husk or pod.
  • The lowest unit in the Roman coinage, the twenty-fourth part of a solidus.
  • A coin of base silver of the Gothic and Lombard kings of Italy.
'Siliqua' comes from a Latin word meaning 'a pod.'
Related